Ocular Therapeutix IncOCUL
Price$7.29Intrinsic value$6.1715% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $6.17median of 2 methodsbased on filings through 30 Jun 2026
Market Price $7.29Price as of 1 Oct 2026
Margin of Safety -15.4%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: 12.0%/yr (balance of the path).10.6% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 611.7%Yr 711.4%Yr 811.1%Yr 910.8%Yr 1010.6%
12.0% → 10.6%
Years 11–20: glide to long-run rate
Per-year rates
Yr 119.8%Yr 129.0%Yr 138.3%Yr 147.5%Yr 156.8%Yr 166.0%Yr 175.3%Yr 184.5%Yr 193.8%Yr 203.0%
10.6% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Discount rate (cost of equity) 9.2%
Volatility vs market (adjusted beta)0.95

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetOcular Therapeutix IncOCULHealth Care
Valuation
P/E—
P/S42.8×
P/B4.7×
EV / Revenue31.3×
EV / EBITDA—
Profitability
Gross margin—
Operating margin-603.0%
Net margin-579.1%
FCF margin-490.1%
Returns
ROE-58.0%
ROA-44.9%
ROIC—
Growth
Revenue growth (YoY)-18.3%
5-yr fwd EPS growth10.6%
Financial strength
Debt / Equity—
Current ratio13.11×
Altman Z-Score6.0
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.